Reframe Daily: Heart pill cuts deaths; weekly shot helps kids with type 2 diabetes; new psoriasis pill beats a top rival

Reframe Daily—curated by Christin Chong (neuroscience PhD, Buddhist chaplain, healthtech strategy consultant)—delivers optimistic and credible healthtech updates you won’t find in most popular news outlets, from sources scientists and healthcare providers read and trust.

Today in one sentence:  A heart-failure pill already on shelves lowered deaths after a recent flare-up; a once-weekly shot helped kids and teens with type 2 diabetes drop A1C and weight; a new pill beat a leading psoriasis drug in head-to-head trials; a treatment for a rare kidney disease cleared a major study; and a lower dose of an immune therapy helped preserve insulin in people newly diagnosed with type 1 diabetes.

Pop in the Discord to chat about health →
https://forms.gle/tN3oabFTsDF21VnS8

Weekly personal shares from Christin here →
http://christin.substack.com/

Good news: A heart-failure pill that’s already on shelves cut the risk of dying, giving doctors a stronger reason to use it after a recent flare-up.

Vericiguat in patients with chronic heart failure and reduced ejection fraction after a recent worsening event (VICTOR): a randomised, phase 3 trial. 

Market readiness: 🙂🙂🙂🙂🙂 (already FDA-approved; phase 3 data in high-risk patients strengthens use after worsening events)

Good news: An oral psoriasis medicine beat an approved competitor and placebo, hinting at clearer skin with a simple daily pill.

Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in moderate-to-severe plaque psoriasis: phase 3 ICONIC-ADVANCE trials. 

Market readiness: 🙂🙂🙂🙂 (two late-stage trials with head-to-head superiority; not yet US-approved but close to filing)

Good news: Kids and teens with type 2 diabetes saw big drops in A1C and weight on a once-weekly shot, pointing to a new option for hard-to-treat youth.

Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. 

Market readiness: 🙂🙂🙂🙂 (successful phase 3 for a drug already approved in adults; pediatric label expansion likely next)

Good news: A targeted pill for a rare kidney disease lowered disease activity in a rigorously run trial—promising for people with few options.

Iptacopan for complement 3 glomerulopathy: a randomised, double-blind, placebo-controlled phase 3 trial. 

Market readiness: 🙂🙂🙂🙂 (positive phase 3; US indication status evolving, but data support real-world adoption once approved for this use)

Good news: A much lower dose of an immune therapy preserved insulin in new-onset type 1 diabetes—with fewer side effects—making care easier to tolerate.

Minimum effective low dose of antithymocyte globulin in recent-onset type 1 diabetes: a randomised, adaptive trial. 

Market readiness: 🙂🙂🙂 (controlled clinical data but not a standard US treatment for T1D yet; dosing optimization could speed adoption in trials/centers)

Thank you for taking the time to take care of yourself and your loved ones.